source
- FDA grants accelerated approval to Bristol Myers' iberdomide for relapsed or refractory multiple myelomaThe U.S. Food and Drug Administration has issued an accelerated approval for iberdomide, a small-molecule therapy developed by Bristol Myers Squibb. The approval targets patients with multiple mye…
- Neurocrine’s rare-disease drug approved but later linked to deaths and serious side effectsNeurocrine Biosciences received regulatory approval for a rare‑disease therapy after a small clinical trial showed modest efficacy and side effects that were considered manageable. The decision was…